Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission
Authors: Rutt Chuachoowong
Nathan Shaffer
Wimol Siriwasin
Pongsakdi Chaisilwattana
Nancy L. Young
Philip A. Mock
Sanay Chearskul
Naris Waranawat
Thongpoon Chaowanachan
John Karon
R. J. Simonds
Timothy D. Mastro
Mahidol University
Rajavithi Hospital
Thailand Ministry of Public Health
HIV/AIDS Collaboration
Centers for Disease Control and Prevention
Keywords: Medicine
Issue Date: 26-Jan-2000
Citation: Journal of Infectious Diseases. Vol.181, No.1 (2000), 99-106
Abstract: Human immunodeficiency virus (HIV) levels in cervicovaginal lavage (CVL) and plasma samples were evaluated in relation to perinatal transmission in a randomized placebo-controlled trial of brief antenatal zidovudine treatment. Samples were collected at 38 weeks' gestation from 310 women and more frequently from a subset of 74 women. At 38 weeks, after a 2-week treatment period, CVL HIV-1 was quantifiable in 23% and 52% of samples in the zidovudine and placebo groups, respectively (P < .001). The perinatal transmission rate was 28.7% among women with quantifiable CVL HIV-1 and high plasma virus levels (>10,000 copies/mL) and 1% among women without quantifiable CVL HIV-1 and with low plasma virus levels (P < .001). A 1-log increase in plasma HIV-1 increased the transmission odds 1.8 and 6.1 times (95% confidence interval, 0.9-3.5 vs. 2.4-15.4) for women with and without quantifiable CVL HIV-1, respectively (P = .03). CVL HIV-1 is an independent risk factor for perinatal HIV-1 transmission.
ISSN: 00221899
Appears in Collections:Scopus 1991-2000

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.